Legend Biotech Corp (LEGN)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $3.39B
Last updated: Nov 17, 2026 at 11:06 AM ET
Legend Biotech Corp (LEGN) Financials: Revenue, Profit and Cash Flow
Legend Biotech reported revenue of $1.03B for the fiscal year ended Dec 31, 2025, up 64.0% from the year before. That year, net income was -$296.80M with a net margin of -28.8%, operating cash flow was -$100.47M and free cash flow was -$168.04M. The quarter ended Sep 30, 2026 had revenue of $359.50M and net income of $51.70M.
Revenue and Margins
The operating margin was -13.3% in the fiscal year ended Dec 2025. Over the 8 years to Dec 2025, revenue grew from $23.59M, a compound annual rate of 60.3%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | $1.03B | +64.0% | 60.3% | -13.3% | -28.8% |
| Dec 2024 | $627.24M | +120.0% | 62.6% | -48.3% | -28.2% |
| Dec 2023 | $285.14M | +143.7% | 49.4% | -154.1% | -181.8% |
| Dec 2022 | $117.00M | +70.0% | 44.1% | -389.4% | -381.5% |
| Dec 2021 | $68.83M | -8.2% | 100.0% | -570.0% | -586.4% |
| Dec 2020 | $75.00M | +21.4% | 100.0% | -417.8% | -355.2% |
| Dec 2019 | $61.80M | +25.8% | 100.0% | -214.4% | -164.4% |
| Dec 2018 | $49.13M | +108.2% | 100.0% | -3.1% | -5.7% |
| Dec 2017 | $23.59M | N/A | 100.4% | 58.4% | 39.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss widened from the year before. In the quarter ended Sep 2026, net income turned positive after a loss in the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.03B | $627.24M | $285.14M | $117.00M | $68.83M | $75.00M | $61.80M | $49.13M | $23.59M |
| Cost of revenue | $408.10M | $234.58M | $144.21M | $65.36M | $313.35M | $232.16M | N/A | N/A | -$96.00K |
| Gross profit | $620.80M | $392.66M | $140.93M | $51.64M | $68.83M | $75.00M | $61.80M | $49.13M | $23.69M |
| Research and development | $414.70M | $413.54M | $382.22M | $335.65M | $313.35M | $232.16M | $161.94M | $60.64M | $8.20M |
| Operating income | -$136.50M | -$303.24M | -$439.49M | -$455.62M | -$392.29M | -$313.35M | -$132.51M | -$1.53M | $13.78M |
| Net income | -$296.80M | -$177.03M | -$518.25M | -$446.35M | -$403.58M | -$266.37M | -$101.59M | -$2.78M | $9.37M |
| EBITDA | N/A | -$113.16M | N/A | -$416.54M | N/A | -$298.16M | -$127.25M | $149.00K | $14.06M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $359.50M | $387.50M | $305.10M | $306.38M | $272.33M | $255.06M | $195.05M | $186.52M | $160.21M | $186.52M | $93.99M | $79.46M |
| Gross profit | $211.90M | $250.10M | $129.20M | $182.92M | $157.02M | $157.07M | $123.71M | $112.60M | $104.74M | $136.07M | $39.25M | $47.01M |
| Operating income | $46.80M | $57.70M | -$49.80M | -$20.60M | -$43.45M | -$21.88M | -$50.65M | -$74.39M | -$70.05M | -$41.97M | -$117.86M | -$119.85M |
| Net income | $51.70M | $33.20M | -$54.30M | -$30.82M | -$39.69M | -$125.38M | -$100.92M | $26.28M | -$125.32M | -$18.20M | -$59.79M | -$144.82M |
Balance Sheet
As of Dec 2025, cash and equivalents exceeded short-term debt of $326.50M by $575.40M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.73B | $1.67B | $1.85B | $1.33B | $1.12B | $722.09M | $287.71M | $429.05M | $238.69M |
| Current assets | $1.25B | $1.28B | $1.50B | $1.10B | $949.85M | $593.94M | $207.10M | $326.96M | $230.90M |
| Cash and equivalents | $901.90M | $286.75M | $1.28B | $786.03M | $688.94M | $456.07M | $83.36M | $210.17M | $2.12M |
| Total liabilities | $731.60M | $629.61M | $597.24M | $586.65M | $353.52M | $122.27M | $410.58M | $420.40M | $226.53M |
| Short-term debt | $326.50M | $4.79M | $3.17M | $3.56M | $911.00K | $1.79M | $1.03M | $373.00K | $64.00K |
| Long-term debt | N/A | $301.20M | $281.33M | $260.93M | $120.46M | N/A | N/A | N/A | N/A |
| Shareholder equity | $1.00B | $1.04B | $1.25B | $744.31M | $765.94M | $597.77M | -$122.87M | $8.65M | $12.17M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | $1.68B | $1.75B | $1.60B | $1.73B | $1.71B | $1.69B | $1.62B | $1.67B | $1.74B | $1.80B | $1.78B | $1.85B |
| Total liabilities | $408.70M | $521.32M | $629.02M | $731.60M | $701.69M | $654.38M | $597.90M | $629.61M | $619.72M | $639.18M | $611.05M | $597.24M |
| Cash and equivalents | $460.70M | $672.92M | $646.42M | $901.90M | $278.89M | $266.59M | $441.70M | $286.75M | $459.28M | $201.25M | $897.57M | $1.28B |
| Shareholder equity | $1.27B | $1.23B | $967.73M | $1.00B | $1.01B | $1.04B | $1.02B | $1.04B | $1.12B | $1.16B | $1.16B | $1.25B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 |
|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$100.47M | -$144.03M | -$393.28M | -$201.28M | -$198.47M | -$223.00M | -$83.06M | $307.68M | -$2.38M |
| Capital expenditures | $67.58M | $14.11M | $22.72M | $22.27M | $45.40M | $30.28M | $39.17M | $21.02M | $887.00K |
| Free cash flow | -$168.04M | -$158.14M | -$416.00M | -$223.56M | -$243.87M | -$253.29M | -$122.23M | $286.66M | -$3.26M |
| Investing cash flow | $711.48M | -$850.54M | $92.79M | -$77.09M | -$194.98M | -$24.17M | -$58.65M | -$102.26M | -$827.00K |
| Financing cash flow | -$300.79K | $5.70M | $791.49M | $377.98M | $626.66M | $618.88M | $14.67M | $2.50M | $3.32M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$35.90M | -$20.90M | -$85.35M | -$105.64M | $28.80M | -$13.04M | -$103.75M | -$82.08M | -$75.82M | -$1.65M | $15.52M | -$95.64M |
| Capital expenditures | $5.60M | $20.62M | $25.98M | $20.92M | $5.00M | $9.22M | $2.00M | $2.38M | $2.06M | $3.42M | $6.25M | $6.85M |
| Free cash flow | -$41.50M | -$41.52M | -$111.33M | -$126.56M | $23.80M | -$22.27M | -$105.76M | -$84.46M | -$77.89M | -$5.07M | $9.27M | -$102.49M |
Frequently Asked Questions About LEGN
What is Legend Biotech's annual revenue?
Legend Biotech reported revenue of $1.03B for the fiscal year ended Dec 31, 2025.
How fast is Legend Biotech's revenue growing?
Revenue was up 64.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 106.4%.
Is Legend Biotech profitable?
No. Legend Biotech reported net income of -$296.80M for the fiscal year ended Dec 31, 2025, with a net margin of -28.8%.
How much free cash flow does LEGN generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of -$100.47M minus capital expenditures of $67.58M produced free cash flow of -$168.04M.
How much debt does Legend Biotech have?
The balance sheet dated Dec 31, 2025 reported short-term debt of $326.50M and cash and equivalents of $901.90M.
LEGN pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors